CLEVELAND — The Food and Drug Administration has approved expanded use of Addyi, a medication designed to address low sexual desire in women, now including post-menopausal women under age 65.

Sprout Pharmaceuticals, the drug’s manufacturer, said the approval represents a significant development in understanding women’s sexual health. Addyi treats hypoactive sexual desire disorder, a condition characterized by persistently low sexual desire. The FDA initially approved the medication in 2015 for premenopausal women. Six years later, Health Canada approved its expanded use for post-menopausal women, paving the way for this U.S. approval.

In separate FDA news, the agency is considering changes to dietary supplement labeling requirements that could affect how consumers see safety warnings. Currently, supplement packages must display a disclaimer next to every health claim stating the FDA has not evaluated the statement and the product is not intended to diagnose, treat, cure or prevent disease. The proposed change would require this warning only once per package rather than repeating it with each claim.

The FDA says the modification would reduce label clutter and costs for manufacturers. However, some medical experts express concern that consolidated warnings could be easier for consumers to overlook. The change carries particular significance given that more than three-quarters of Americans take dietary supplements, and unlike prescription drugs, these products are not reviewed for safety and effectiveness before reaching store shelves. Approximately 100,000 supplement products are currently available nationwide.

Meanwhile, researchers at Case Western Reserve University and University Hospitals have launched the first comprehensive study examining nail fungus in athletes. The condition affects athletes at rates 2.5 times higher than the general population, according to research published in the Journal of the American Academy of Dermatology.

Dr. James Voos, chairman of Orthopedic Surgery at University Hospitals, explained that nail fungus can alter athletic performance by affecting gait, reducing training consistency and impacting competitive outcomes. The six-month study will survey 100 to 200 collegiate and professional athletes across multiple sports, gathering data on how the fungal infections affect daily activities, confidence and athletic function.

Dr. Mahmoud Ghannoum, director of the Center for Medical Mycology at Case Western Reserve and the study’s lead researcher, noted there is limited data showing prevalence rates across different sports despite high-risk factors. Athletes face increased exposure due to warm, moist environments created by intense training, restrictive footwear and shared facilities. Initial results are expected by June, with findings potentially benefiting military personnel and other groups facing similar risk factors.